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Four previous reviews for this journal (1985,1
1989,2 1994,3 20044) and 3 others published more
recently5–7 give a good sense of the changes that have
occurred in the last 20 years in the study of drug-
induced immune hemolytic anemia (DIIHA). These
changes include new drugs that cause DIIHA,
incidence of the involvement of certain drugs,revisions
to proposed mechanisms involved in DIIHA, and new
information on individual drugs. In our review in
2005,6 we emphasized the changing spectrum of drugs
associated with DIIHA. In the 10-year period 1969 to
1979, methyldopa was responsible for 67 percent, and
high-dose intravenous penicillin for 23 percent, of the
DIIHAs we encountered. In the 1995 to 2004 period,
82 percent of DIIHAs were associated with second- and
third-generation cephalosporins (72% of these were
associated with cefotetan, and 10% with ceftriaxone).
Drug-induced antibodies are of two types: (1) drug-
independent antibodies (no drug is needed to
demonstrate the presence of antibody, i.e., react
similarly to true autoantibodies); and (2) drug-
dependent antibodies, which require drug to be
present to demonstrate the antibody. The drug can be
covalently bound to the RBC membrane,or exist free in
the plasma. Thus, drug-dependent antibodies can be
demonstrated by testing the patient’s plasma or serum,
or an eluate from DAT-positive RBCs with RBCs coated
with drug in vitro, or testing the serum in the presence
of a drug solution and RBCs or both.
In Tables 1 and 2,we list 125 drugs that we believe
have reasonable evidence to support a drug-associated
immune etiology for DIIHA or positive DATs.8–151 We
cannot include every reference, so we selected the first
report that contained reasonable data and further
references that added important extra data. Table 1
contains a list of 108 drugs in which drug-dependent
antibodies (i.e., antibodies that only react with RBCs
when drug is present, either bound to the RBCs, or
when added to the patient’s serum,and target RBCs8–124)
were detected. Twenty-six percent of the drugs were
associated with antibodies that only reacted with drug-
coated RBCs; 39 percent were associated with
antibodies that only reacted in the presence of drug,
and 35 percent were associated with antibodies that
reacted with drug-treated RBCs or in the presence of
drug or both. One surprising result was that 44
percent of these reactions were accompanied by
reactions against untreated RBCs without the addition
of drugs in vitro. We believe that these reactions are
not caused by drug-independent autoantibodies such
as those listed inTable 2,but rather are a subpopulation
of drug-dependent antibodies reacting with the drug
plus RBC membrane proteins and not needing drug for
their demonstration, or are caused by circulating drug,
or drug–anti-drug complexes (see later).
Figure 1 shows the concept of the unifying
hypothesis,5,67,152,153 based on Landsteiner’s work on
antibody populations induced by haptens (small
molecules such as drugs).154 One population of
antibodies reacts with the hapten (drug) alone;another
population reacts with part drug plus carrier (protein
on RBC membrane). This epitope may be mostly the
carrier as illustrated on the left side of the cartoon.
Antibodies that react with drug alone can be detected
using RBCs coated with the drug. Some investigators
call this the “hapten mechanism.” This makes no sense
to us as all drugs are haptens (i.e., small molecules that
require a carrier such as a protein to be immunogenic).
The term was first used to describe the penicillin
antibody reactions,but at that time few drug antibodies
had been described and little was known of drug
immunology. (For further discussion of this see pages
263–7 of Petz and Garratty.5) Antibodies reacting with
an epitope such as the one illustrated on the bottom
right side of the cartoon will react when the patient’s
serum is mixed with drug and RBCs (this mechanism is
sometimes called the “immune-complex” mechanism).
When the epitope is mainly composed of the RBC
membrane, then the antibody may react with RBCs
without any drug being present and appears to be a
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Table 1. Drugs associated with cases of IHA or positive DAT or both in which drug-dependent antibodies were detected*
Number Reactive
of references without
[single (year) Drug- Serum drug
Drug vs. multiple Positive coated + drug Not added
(Alternative name) Reference Therapeutic category (<5, <10, ≥10)] HA DAT RBCs + RBCs reported in vitro
Aceclofenac 8 NSAID Single (1997)   –  – –
Acetaminophen 9, 10 NSAID Multiple (<10)   –  – –
(Paracetamol)
Acyclovir 11 Antiviral Single (2003)    – – –
Aminopyrine 12 NSAID Single (1961)  –  – – –
(Piramidone)
Amoxicillin 13 Antimicrobial Single (1985)    – – –
Amphotericin B 14 Antimicrobial Multiple (<5)   – † – –
Ampicillin 15 Antimicrobial Multiple (<10)     – –
Antazoline 16 Antihistamine Multiple (<5)   –  – –
Aspirin 17 Analgesic, antipyretic, Single (1984)  – –  – –
anti-inflammatory
Azapropazone 18 Antiinflammatory, Multiple (<5)    – – 
(Apazone) analgesic
Buthiazide 19 Diuretic, Single (1984)   – † – –
(Butizide) antihypertensive
Carbimazole 20 Antithyroid Multiple (<5)     – 
Carboplatin‡ 21 Antineoplastic Multiple (<5)     – 
Carbromal 22 Sedative, hypnotic Single (1970) –   – – –
Catechin 23 Antidiarrheal Multiple (≥10)    † – 
((+)-Cyanidanol-3)
(Cianidanol)
Cefamandole 24 Antimicrobial Single (1985)    – – –
Cefazolin 25 Antimicrobial Multiple (<10)    – – –
Cefixime 26 Antimicrobial Single (2000)  –   – –
Cefotaxime‡ 27 Antimicrobial Multiple (<5)     – **
Cefotetan‡ 28–32 Antimicrobial Multiple (≥10)   ¶  – 
Cefoxitin‡ 33 Antimicrobial Multiple (<10)     – 
Cefpirome 34 Antibacterial Single (2005) –  –  – –
Ceftazidime 35 Antimicrobial Multiple (<10)     – 
Ceftizoxime 36 Antimicrobial Multiple (<5)     – **
Ceftriaxone‡ 37, 38 Antimicrobial Multiple (>10)   – † – **
Cefuroxime 39 Antibacterial Multiple (<5)    – – –
Cephalexin 40 Antimicrobial Multiple (5)   ¶ – – –
Cephalothin‡ 41–43 Antimicrobial Multiple (≥10)   ¶  – –
Chloramphenicol 44 Antibacterial Multiple (<5)    – – 
Chlorinated 45 Insecticides Multiple (<10)     – 
hydrocarbons
Chlorpromazine 46 Antiemetic, Multiple (<10)    – – 
antipsychotic
Chlorpropamide‡ 47, 48 Antidiabetic Multiple (<10)   –  – **
Ciprofloxacin 49 Antibacterial Multiple (<10)   –  – 
Cisplatin 50, 51 Antineoplastic Multiple (<10)   ¶  – –
(Cisdiamino-
dichloroplatinum)
Cloxacillin 52 Antibacterial Single (1980) –  – –  
Cyclofenil 53 Gonad-stimulating principle Multiple (<5)   –  – 
Cyclosporin 54 Immunosuppressant Multiple (<5)    – – 
(Cyclosporine)
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Dexchlorpheniramine 55 Antihistaminic Single (1981)   –  – –
maleate
(Chlorpheniramine)
Diclofenac‡ 56–59 NSAID Multiple (≥10)    † – **
Diethylstilbestrol 60 Estrogen Multiple (<5)   –  – –
(Stilboestrol)
Dipyrone 61 NSAID Multiple (<5)     – –
Erythromycin‡ 62 Antimicrobial Multiple (<5    – – –
Etodolac 63 NSAID Single (2000)   – † – –
Ethambutol 11 Antibacterial Single (2003)     – –
Fenoprofen 64 NSAID Single (1988)   –  – **
Fluconazole 11 Antifungal Single (2003)     – –
Fluorescein 65 Injectable dye Single (1993)     – **
Fluorouracil 66 Antineoplastic Multiple (<5)   –  – –
Furosemide 35 Diuretic Multiple (<5) –  –  – –
Glafenine 67, 68 Analgesic Multiple (<5)   – – † 
(Glaphenine)
Hydralazine 69 Antihypertensive Single (1977)    – – –
Hydrochlorothiazide‡ 70 Diuretic Multiple (<10)     – **
9-Hydroxy-methyl- 71 Antineoplastic Multiple (<5)   –  – –
ellipticinium
(Elliptinium acetate)
Ibuprofen 72 NSAID Multiple (<5)   –  – 
Imatinib mesylate 73 Antineoplastic Multiple (<5)    – – –
Insulin 74 Antidiabetic Multiple (<5)    – – –
Isoniazid 75 Antimicrobial Multiple (<10)     – –
Latamoxef 67 Antimicrobial Single (1985)   – –  
(Moxalactam)
Levofloxacin 76 Antibacterial Multiple (<5)     – 
(Ofloxacin)
Mefloquine‡ 77 Antimicrobial Multiple (<5)     – **
Melphalan 78 Antineoplastic Single (1967)  – –  – –
6-Mercaptopurine 79 Anti-neoplastic Single (2000)    – – –
Methadone 80 Analgesic Multiple (<5) –   – – –
Methotrexate 81 Antineoplastic, Multiple (<5)     – 
antirheumatic
Metrizoate-based 82 Multiple (<5)     – 
radiographic contrast
media
Minocycline 83 Antibacterial Single (1994)   –  – –
Nabumetone 84 Antiinflammatory, Single (2003)   – † – 
analgesic
Nafcillin‡ 85 Antimicrobial Multiple (<10)    – – –
Naproxen 86 Antiinflammatory, Multiple (<5)   –  – –
analgesic, antipyretic
Nitrofurantoin 87 Antibacterial Single (1981)  – –  – –
Nomifensine§ 88 Antidepressant Multiple (≥10)   – † – **
Norfloxacin 89 Antimicrobial Single (1999) –   – – –
Oxaliplatin‡ 90, 91 Antineoplastic Multiple (≥10)   ¶  – **
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Penicillin G‡ 93, 94 Antimicrobial Multiple (≥10)     – –
Phenacetin‡ 95 NSAID Multiple (≥10)   –  – 
(Acetophenetidin)
Phenytoin 11 Anticonvulsant, Single (2003)    – – –
(Fenitoine) antiarrhythmic
Piperacillin‡ 96 Antimicrobial Multiple (<10)     – **
Probenecid‡ 97 Uricosuric Multiple (<5)   –  – **
Propyphenazone 98 NSAID Single (1998)   –  – –
Pyrazinamide 11 Antibacterial Single (2003)     – –
Pyrimethamine 11 Antimicrobial Multiple (<5)    – – –
(Pirimetamine)
Quinidine 99 Antiarrhythmic, Multiple (≥10)     – **
antimicrobial
Quinine 95 Antimicrobial Multiple (<10)  – –  – 
Ranitidine 100 Antiulcerative Multiple (<5)     – –
Rifabutin 11 Antibacterial Single (2003)   –  – –
Rifampin‡ 101–103 Antibacterial Multiple (≥10)     – **
(Rifampicin)
Stibophen 105 Antimicrobial Multiple (<5)   –  – –
Streptokinase 106 Thrombolytic Single (1989)    – – 
Streptomycin 107–109 Antimicrobial Multiple (<10)     – 
Sulfasalazine 110 Antiinflammatory Multiple (<5)   –  – –
Sulfisoxazole 11 Antibacterial Single (2003)     – –
Sulindac 111 Antiinflammatory Multiple (<10)     – **
Suprofen 112 NSAID Single (1989)   –  – **
Tartrazine 113 Colorant Single (1979)     – –
Teicoplanin 114 Antimicrobial Single (2004)   –  – 
Temafloxacin§ 115 Antimicrobial Multiple (<5)   –  – –
Teniposide 116 Antineoplastic Single (1982)   –  – 
Tetracycline 117 Antimicrobial Multiple (<10)    – – –
Thiopental sodium 104 Anesthetic Single (1985)  – –  – –
Ticarcillin‡ 118 Antimicrobial Multiple (<5)    – – 
Tolbutamide 119 Antidiabetic Multiple (<5)    – – –
Tolmetin‡ 120 NSAID Multiple (≥10)   –  – **
Triamterene 121 Diuretic Multiple (<5)     – –
Trimellitic 122 Used in preparation of Single (1979)  –  – – –
anhydride resins, dyes, adhesives, etc.
Trimethoprim and 123 Antibacterial Multiple (<5)     – 
sulfamethoxazole‡
Vancomycin 11 Antibacterial Single (2003)   –  – –
Zomepirac 124 NSAID Single (1983)   –  – 
* When a drug antibody is indicated to be reactive by two methods, e.g., vs. drug-treated RBCs and when serum + drug + RBCs are mixed together, this does not necessarily
mean that all examples of antibodies to that drug were detected by both methods. Using ampicillin for example, four reported antibodies reacted with drug-treated RBCs and
were either nonreactive (n = 1) or not tested (n = 3) by the serum + drug + RBCs method, and two antibodies reacted when serum + drug + RBCs were tested but were
nonreactive with drug-treated RBCs.
IHA = immune hemolytic anemia; HA = hemolytic anemia; NSAID = nonsteroidal antiinflammatory drug.
† One or more samples only positive or strongest reactions seen with ex vivo (urine or serum) or metabolite.
‡We have seen cases of DIIHA or positive DAT or both attributable to these.
§ No longer manufactured.
¶ Associated with nonimmunologic protein adsorption (NIPA).
**One or more samples positive possibly owing to the presence of circulating drug or drug–antibody immune complexes.
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drug-independent antibody (autoantibody). We should
emphasize that the latter hypothesis above is our own
and has little experimental data to support it.
Alternative explanations are that these reactions,
without the presence of drug, may be attributable to
drug–immune complexes still present in the plasma,or
enough drug present in the plasma to cause reactions
with drug-dependent antibodies.48,64,65,77,155–160 The
reactions can be differentiated from true
autoantibodies by repeating the testing a few days after
the drug is discontinued; by then, the drug or drug
complexes will no longer be present. If the drug has an
unusually long half-life (e.g.,mefloquine hydrochloride
has a mean half-life of 3 weeks), or if the patient is in
renal failure, then the circulating drug may persist
longer than expected.
Table 2. Drugs associated with cases of IHA or positive DAT or both in which only drug-independent antibodies (autoantibodies) were detected
Number of references More
Drug [single (year) vs. Positive evidence
(Alternative name) Reference Therapeutic category multiple (<5, <10, ≥10)] HA DAT needed
Captopril 125 Antihypertensive Multiple (<5)   
Chaparral 126 Herbal Single (1980)  
Cimetidine 127 Antiulcerative Multiple (<10)   
Cladribine 128 Antineoplastic Multiple (<10)   –
(2-chlorodeoxyadenosine)
Fenfluramine 129 Anorexic Single (1973)   
Fludarabine* 130,131 Antineoplastic Multiple (≥10)   –
Interferon 132 Antineoplastic, antiviral Multiple (≥10)   
Interleukin-2 133 Antineoplastic Multiple (<5)   
Ketoconazole 134 Antifungal Single (1987)   
Lenalidomide 135 Immunomodulatory Single (2006)   
Levodopa 136 Antiparkinsonian Multiple (≥10)   –
(L-dopa)
Mefenamic acid 137 NSAID Multiple (≥10)   –
Mesantoin 138 Anticonvulsant Single (1953)   
(Mephenytoin)
Methyldopa* 139 Antihypertensive Multiple (≥10)   –
Nalidixic acid 140 Antibacterial Multiple (<10)   
Procainamide* 141, 142 Antiarrhythmic Multiple (<10)   –
Tacrolimus 143 Immunosuppressant Multiple (<5)   
IHA = immune hemolytic anemia; HA = hemolytic anemia
*We have seen cases of DIIHA or positive DAT caused by these.
Table 3. Drugs associated with the detection of nonimmunologic protein adsorption onto RBCs
Number of references Drug-dependent
Drug [single (year) vs. Positive antibody(ies)
(Alternative name) Reference Therapeutic category multiple (<5, <10, ≥10)] HA DAT also detected
Cefotetan* 29, 30 Antimicrobial Multiple (≥10)   
Cephalothin* 41, 42 Antimicrobial Multiple (≥10)   
Cisplatin 51 Antineoplastic Multiple (<10)   
Clavulanate potassium* 144, 145 β-Lactamase inhibitor Multiple (<5) –  –
(Clavulanic acid)
Diglycoaldehyde 146, 147 Antineoplastic Multiple (<5) –  –
(INOX)
Oxaliplatin* 91 Antineoplastic Multiple (≥10)   
Sulbactam* 145, 148 β-Lactamase inhibitor Multiple (<5)   –
Suramin 149 Antihelminthic, antiprotozoal Single (1988) – – –
Tazobactam* 150, 151 β-Lactamase inhibitor Multiple (<5)   –
HA = hemolytic anemia
*We have seen cases of DIIHA or positive DAT caused by these.
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Table 2 is a list of 17 drugs that have been
associated with drug-independent antibodies (autoanti-
bodies). Many of these associations are not supported
by very convincing proof that the drug induced the
autoantibodies; idiopathic autoimmune hemolytic
anemia (AIHA) is much more common than DIIHA and
often is not excluded in the reports. It is not possible
to prove the suggestion by laboratory testing as drug
antibodies are not demonstrable, so many of the
reports are based on a hemolytic anemia or a positive
DAT or both developing after drug therapy and a
response to stopping the drug. This could be
coincidence. If it was a true phenomenon, then giving
the drug again should restart the problem. For obvious
reasons, this has not been tried often. It was tried,with
methyldopa, and the AIHA occurred again,proving that
there was a true relationship of drug and AIHA. Petz et
al.161 showed that it was a fallacy in two patients with
suspected cimetidine-induced AIHA. When the
patients’ hemolytic anemia resolved after dis-
continuation of the drug, they were treated again with
cimetidine (55 days in one patient and 24 months in
the second patient) and no hemolytic anemia recurred,
suggesting the drug had not caused the AIHA. These
findings cast doubt on many of the drugs in this table.
Often,when the drugs are stopped the patients are also
taking steroids, so it is difficult to be certain what
caused the recovery.
Positive Antiglobulin Tests Caused by
Nonimmunologic Adsorption of Protein
During the last few years, we have become very
interested in the nonimmunologic adsorption of
protein onto RBCs leading to positive antiglobulin
tests, and perhaps DIIHA. The reaction can mislead the
investigator into thinking that an antibody to RBC
antigens is being detected. The first drug shown to
cause this phenomenon was the first cephalosporin
(cephalothin). In 1971, Spath et al.162 showed that
cephalothin-treated RBCs adsorbed IgG, C3, albumin,
fibrinogen, etc., after incubation in normal plasma; the
proteins could be detected by the antiglobulin test.
This is because the drug can modify the RBC
membrane to adsorb proteins nonimmunologically
(see Figure 2). Table 3 shows eight other drugs that
cause the same effect. Up to about 1996, we believed
that this was an in vitro phenomenon that caused us in
vitro problems, but that it had no clinical significance.
We now believe this mechanism can cause hemolytic
anemia. RBCs having IgG on their membrane, caused
by nonimmunologic adsorption, yield positive mono-
cyte monolayer assays (MMA), and we have published
data showing that the mechanism can be the probable
cause of decreased RBC survival in patients taking
drugs that contain β-lactamase inhibitors (clavulanate,
sulbactam, tazobactam).5,150, 151
This mechanism can lead to confusion in the
workup of DIIHAs. The patient’s serum may react with
RBCs coated with the drugs listed in Table 3, but this
means nothing as normal sera will also react with these
same drug-coated RBCs. This is why it is important to
use pooled normal plasma or serum as a negative
control in any tests on drug-coated RBCs. Remember,
Fig. 1. Proposed unifying hypothesis of drug-induced antibody
reactions.The thicker,darker lines represent antigen-binding sites
on the Fab region of the drug-induced antibody. Drugs (haptens)
bind loosely (or firmly) to RBC membranes,and antibodies can be
made to the drug (producing in vitro reactions typical of a drug
adsorption [penicillin-type] reaction);membrane components, or
mainly membrane components (producing in vitro reactions
typical of autoantibody); or part-drug, part-membrane
components (producing an in vitro reaction typical of the so-
called immune complex mechanism).
Fig. 2. Nonimmunologic adsorption of proteins onto RBCs.Drugs might
change the RBC membrane so that many proteins attach to the
membrane, leading to a positive DAT and, possibly, to DIIHA.
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for five of these drugs, there is no drug antibody
involved, so one can only suggest to the physician that
this mechanism could be involved and let the physician
have the relevant references.
Another complication is that drugs containing
β-lactamase inhibitors also contain antibiotics (Zosyn
contains tazobactam plus piperacillin; Unasyn contains
sulbactam plus ampicillin; Timentin contains clavu-
lanate plus ticarcillin; Augmentin contains clavulanate
plus amoxicillin). These antibiotics can also cause
DIIHA through more typical mechanisms.5,163
Piperacillin is an exception to the typical reaction of
penicillins in that it is detected best by the “immune
complex” method.7,164,165 An unusual aspect of
piperacillin is that most normal donor and patient sera
appear to have piperacillin antibodies as they react
with piperacillin-coated RBCs, and this is not caused by
nonimmunologic adsorption of protein. Normal sera
also contain antibodies that react with penicillin- and
cefotetan-coated RBCs,5,166 but fewer sera react with
these than with piperacillin-coated RBCs. It seems that
we all are exposed to antigens identical, or very similar,
to some penicillin-like structures in our environment.
A few technical hints when investigating DIIHA:
1. A positive DAT with a nonreactive eluate
should not automatically suggest an invest-
igation of DIIHA. Much more common causes
are cytophilic IgG167,168; passively transfused
anti-A or anti-B or both (e.g., when A, B, or AB
patients receive group O RBCs, platelet
products from donors not ABO identical, IVIG,
or intravenous anti-D immunoglobulin).169
Remember, drug-induced positive DATs and
AIHA are rare.
2. Prepare penicillin-treated RBCs at high pH
(e.g., 8–10), but prepare cephalosporin-treated
RBCs at pH 7 to 7.4 to reduce nonimmunologic
binding of protein.5
3. Some drugs do not fit the pattern seen with
other members of the same family:
• It is not possible to prepare ceftriaxone-
coated RBCs; the “immune complex”method
must be used.
• Special conditions are needed to prepare
nafcillin- and erythromycin-coated
RBCs.62,85,170,171
• Piperacillin-coated RBCs will be agglutinated
by many normal sera; thus, piperacillin anti-
bodies in serum should only be tested by the
“immune complex” mechanism.165 RBC
eluates can be tested with piperacillin-coated
RBCs.
4. Some drugs contain more than one chemical,
e.g., Zosyn contains an antibiotic piperacillin
and a β-lactamase inhibitor, tazobactam. It is
important to test each drug separately to
determine the specificity of the antibody. In
addition to the problem with piperacillin
(discussed in an earlier section), there is a
special problem with the β-lactamase
inhibitors. The patient’s serum may react with
drug-treated RBCs, suggesting a drug antibody;
unfortunately, all normal sera will also react.
This is because the drug can modify the RBC
membrane to adsorb proteins nonimmuno-
logically (see earlier section). Thus, it is
essential to always use a pool of normal sera as
a negative control when evaluating any DIIHA
serologic results.
5. Antiglobulin test reactivity of a pooled normal
sera control with drug-treated RBCs indicates
the possible presence of nonimmunologic
protein adsorption (NIPA).5 If this occurs, the
normal sera control and the patient’s serum
should be diluted 1 in 20 in saline and retested
(the 1 in 20 dilutions should not contain
enough protein to cause detectable NIPA). For
testing of cefotetan-treated RBCs, the patient’s
serum should be diluted 1 in 100 because many
normal sera react with cefotetan-treated RBCs,
even at a 1 in 20 dilution.166
6. If a patient’s serum contains a drug-
independent antibody, the presence of a drug-
dependent antibody can be demonstrated by
performing an autologous or allogeneic ad-
sorption to remove the drug-independent
antibody and then testing the adsorbed serum
by the usual methods to detect drug antibodies.
7. When looking at a patient’s drug history, in
addition to considering the drugs that the
patient is receiving at the time of the hemolytic
anemia, it may also be important to determine
what drugs the patient may have received 1 to
2 weeks previously (e.g., in surgery).
8. It has been reported that 6% albumin can be
used to solubilize drugs that have poor water
solubility.172 If the drug (e.g., cephalothin,
cefotetan) bonds covalently to proteins (e.g.,
albumin), then reduced binding of the drug to
RBCs can occur.173 Thus, this method of
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solubilizing drug in 6% albumin should be used
cautiously,e.g.,only when the drug is known to
not be soluble in water and with the
knowledge of its protein binding affinity
(information about solubility and protein
binding can usually be found in the Merck
Index174 or the Physicians’ Desk Reference175 or
both).
9. Some drug antibodies have been reported to be
detectable in vitro only when ex vivo
preparations of the drug, e.g., urine or serum
from a person taking the drug, have been used
for the testing (by the “serum plus drug plus
RBCs”method).14,19,20,63,84,176–178 This is thought to
be caused by the antibody being directed
against a metabolite of the drug rather than the
native drug and the presence of the appro-
priate drug metabolite(s) in the ex vivo
preparation(s). Drug antibodies that have been
reported to only be detected in the presence of
an ex vivo preparation have been indicated
with a footnote under the “serum plus drug
plus RBCs”method in Table 1.
10. One important endpoint in testing for the
presence of drug antibodies is hemolysis. A
serum sample must be used for this testing
(EDTA binds calcium, which is needed for the
complement cascade; thus, EDTA plasma
cannot be used for the detection of hemolysis).
Many blood banks now use EDTA plasma for
their routine testing, and the patient will have
to have blood drawn again to obtain the
necessary serum sample for a proper DIIHA
workup.
11. If a patient’s serum is nonreactive with drug-
treated RBCs and there is no positive control
available to confirm the presence of the drug
on the drug-treated RBCs, then no interpre-
tation of the negative result can be made.
12. When a drug antibody in the serum is detected
by testing drug-treated RBCs, it is important to
confirm the presence of that drug antibody in
an eluate prepared from the patient’s RBCs to
conclude that the drug was the cause of the
patient’s hemolytic anemia.
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